Sarina A Piha-Paul

List of Publications by Citations

186 papers	11,358 citations	49 h-index	104 g-index
197 ext. papers	15,401 ext. citations	6.1 avg, IF	6.09 L-index

#	Paper	IF	Citations
186	IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. *Journal of Clinical Investigation*, **2017**, 127, 2930-2940	15.9	1426
185	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *Journal of Clinical Oncology* , **2020**, 38, 1-10	2.2	786
184	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncology, The*, **2020**, 21, 1353-1365	21.7	500
183	Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. *Clinical Cancer Research*, **2012**, 18, 6373-83	12.9	391
182	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. *Nature*, **2018**, 554, 189-194	50.4	388
181	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. *Journal of Clinical Oncology*, **2019**, 37, 1470-1478	2.2	364
180	T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. *Journal of Clinical Oncology*, **2019**, 37, 318-327	2.2	346
179	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. *Journal of Clinical Oncology*, **2015**, 33, 2753-62	2.2	295
178	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. *Molecular Cancer Therapeutics*, **2011**, 10, 558-65	6.1	281
177	AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. *Science Translational Medicine*, **2015**, 7, 314ra185	17.5	268
176	Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. *Journal of Clinical Oncology*, **2017**, 35, 4035-4041	2.2	242
175	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. *Cancer Research*, **2013**, 73, 276-84	10.1	221
174	Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. *Journal of Clinical Oncology*, **2018**, 36, 61-67	2.2	190
173	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. *Cell Reports*, **2014**, 6, 377-87	10.6	186
172	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. *Clinical Cancer Research*, **2018**, 24, 2804-2811	12.9	167
171	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. *Annals of Oncology*, **2018**, 29, 1807-1813	10.3	165
170	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. *Cancer Research*, **2016**, 76, 3690-701	10.1	154

169	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. *Cancer Discovery*, **2016**, 6, 1352-1365	24.4	150
168	Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. *Clinical Cancer Research*, **2014**, 20, 4827-36	12.9	150
167	MABp1, a first-in-class true human antibody targeting interleukin-1□n refractory cancers: an open-label, phase 1 dose-escalation and expansion study. *Lancet Oncology, The*, **2014**, 15, 656-66	21.7	141
166	BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. *Thyroid*, **2015**, 25, 71-7	6.2	140
165	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. *Annals of Oncology*, **2017**, 28, 1036-1041	10.3	138
164	A decision support framework for genomically informed investigational cancer therapy. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	135
163	Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. *Clinical Cancer Research*, **2019**, 25, 2033-2041	12.9	125
162	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. *PLoS ONE*, **2017**, 12, e0189848	3.7	120
161	Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. *Gynecologic Oncology*, **2019**, 152, 243-250	4.9	118
160	Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. *Journal of Thoracic Oncology*, **2020**, 15, 618-627	8.9	116
159	STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial **2018**, 6, 119		109
158	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. *International Journal of Cancer*, **2020**, 147, 2190-2198	7.5	107
157	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. *Journal of Clinical Oncology*, **2016**, 34, 1764-71	2.2	102
156	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. *Investigational New Drugs*, **2018**, 36, 638-646	4.3	102
155	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. *Clinical Cancer Research*, **2018**, 24, 181-188	12.9	89
154	Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2018**, 41, 1083-1088	2.7	88
153	P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. *Oncotarget*, **2013**, 4, 705-14	3.3	87
152	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. *Oncotarget*, **2015**, 6, 12809-21	3.3	77

151	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. *Breast Cancer Research*, **2019**, 21, 78	8.3	75
150	PIK3CA mutations in advanced cancers: characteristics and outcomes. *Oncotarget*, **2012**, 3, 1566-75	3.3	71
149	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. *Clinical Cancer Research*, **2020**, 26, 2124-2130	12.9	69
148	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. *BMC Cancer*, **2019**, 19, 196	4.8	68
147	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. *JCO Precision Oncology*, **2017**, 2017,	3.6	67
146	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials **2017**, 5, 100		67
145	First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. *Clinical Cancer Research*, **2019**, 25, 6309-6319	12.9	65
144	A Deep Learning Framework for Predicting Response to Therapy in Cancer. *Cell Reports*, **2019**, 29, 3367-3373.e4	16.6	63
143	Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. *Clinical Cancer Research*, **2012**, 18, 2922-9	12.9	62
142	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. *JNCI Cancer Spectrum*, **2020**, 4, pkz093	4.6	62
141	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. *Molecular Cancer Therapeutics*, **2016**, 15, 1397-404	6.1	61
140	Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. *Annals of Oncology*, **2018**, 29, 1445-1453	10.3	60
139	Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. *Cancer*, **2020**, 126, 3021-3030	6.4	52
138	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. *Molecular Cancer Therapeutics*, **2016**, 15, 2475-2485	6.1	49
137	Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. *Current Pharmaceutical Biotechnology*, **2014**, 15, 475-85	2.6	47
136	Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. *European Journal of Cancer*, **2015**, 51, 1865-73	7.5	46
135	Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. *Investigational New Drugs*, **2015**, 33, 621-31	4.3	45
134	Phase 2 study of pembrolizumab in patients with advanced rare cancers **2020**, 8,		45

133	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. *Clinical Cancer Research*, **2017**, 23, 3657-3666	12.9	44
132	Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. *Journal of Clinical Oncology*, **2011**, 29, e727-30	2.2	43
131	FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. *PLoS ONE*, **2014**, 9, e89388	3.7	42
130	Efficacy and Determinants of Response to HER Kinase Inhibition in -Mutant Metastatic Breast Cancer. *Cancer Discovery*, **2020**, 10, 198-213	24.4	41
129	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies **2017**, 5, 35		41
128	A phase 1 study of anti-TGF receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, **2017**, 79, 673-680	3.5	40
127	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. *Cancer*, **2016**, 122, 3401-3409	6.4	40
126	Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. *Cancer Chemotherapy and Pharmacology*, **2014**, 73, 495-501	3.5	39
125	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. *Oncotarget*, **2017**, 8, 39254-39267	3.3	38
124	Clinical next generation sequencing to identify actionable aberrations in a phase I program. *Oncotarget*, **2015**, 6, 20099-110	3.3	38
123	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. *Oncotarget*, **2015**, 6, 26886-94	3.3	38
122	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. *Oncotarget*, **2016**, 7, 67521-67531	3.3	36
121	Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. *Oncotarget*, **2014**, 5, 3029-38	3.3	36
120	Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. *Annals of Oncology*, **2017**, 28, 642-650	10.3	35
119	Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. *Molecular Cancer Therapeutics*, **2013**, 12, 2857-63	6.1	35
118	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. *Clinical Cancer Research*, **2020**, 26, 1237-1246	12.9	33
117	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. *BMC Cancer*, **2015**, 15, 713	4.8	33
116	Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. *Oncotarget*, **2013**, 4, 118-27	3.3	31

115	Signature program: a platform of basket trials. *Oncotarget*, **2018**, 9, 21383-21395	3.3	30
114	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. *Clinical Cancer Research*, **2020**, 26, 1247-1257	12.9	29
113	Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. *Oncotarget*, **2013**, 4, 156-65	3.3	29
112	Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 973-7	3.5	28
111	Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. *Molecular Cancer Therapeutics*, **2013**, 12, 2167-75	6.1	27
110	Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. *Oncotarget*, **2014**, 5, 1846-55	3.3	27
109	SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	26
108	Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. *Clinical Breast Cancer*, **2014**, 14, 468-74	3	25
107	Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. *Cancer*, **2014**, 120, 2164-73	6.4	25
106	Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. *Investigational New Drugs*, **2014**, 32, 465-72	4.3	24
105	A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. *Clinical Cancer Research*, **2015**, 21, 5235-44	12.9	23
104	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. *Lung Cancer*, **2018**, 120, 137-141	5.9	22
103	A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. *Investigational New Drugs*, **2013**, 31, 918-26	4.3	22
102	Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. *Investigational New Drugs*, **2013**, 31, 1505-13	4.3	22
101	Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. *Journal of Clinical Oncology*, **2012**, 30, 2891-6	2.2	22
100	Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. *Oncology*, **2016**, 91, 348-353	3.6	21
99	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. *Investigational New Drugs*, **2015**, 33, 177-86	4.3	20
98	Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. *Oncoscience*, **2014**, 1, 540-9	0.8	20

97	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. *JCI Insight*, **2017**, 2,	9.9	19
96	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. *Clinical Cancer Research*, **2018**, 24, 3845-3856	12.9	19
95	Synthesis of a series of polar, orthogonally protected, disubstituted amino acids. *Tetrahedron Letters*, **1997**, 38, 4013-4016	2	19
94	Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. *Anticancer Research*, **2014**, 34, 1939-45	2.3	19
93	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. *Oncotarget*, **2016**, 7, 23227-38	3.3	19
92	Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. *Cancer Chemotherapy and Pharmacology*, **2013**, 71, 193-202	3.5	18
91	Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. *Oncologist*, **2013**, 18, 1315-20	5.7	17
90	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. *Journal of Hematology and Oncology*, **2019**, 12, 145	22.4	17
89	MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. *Clinical Genitourinary Cancer*, **2015**, 13, e19-26	3.3	16
88	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. *British Journal of Cancer*, **2018**, 118, 763-769	8.7	16
87	Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. *Annals of Oncology*, **2013**, 24, 838-42	10.3	16
86	Clinical Use of Precision Oncology Decision Support. *JCO Precision Oncology*, **2017**, 2017,	3.6	15
85	Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. *Oncotarget*, **2013**, 4, 772-84	3.3	15
84	Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. *Journal of Clinical Oncology*, **2011**, 29, e333-5	2.2	14
83	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. *Investigational New Drugs*, **2018**, 36, 416-423	4.3	13
82	Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. *Investigational New Drugs*, **2014**, 32, 279-86	4.3	13
81	Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. *British Journal of Cancer*, **2018**, 118, 1042-1050	8.7	12
80	Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. *Oncologist*, **2014**, 19, 426-8	5.7	12

79	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. *Cancer Medicine*, **2016**, 5, 3437-3444	4.8	12
78	Intratumoral Injection of -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. *Clinical Cancer Research*, **2021**, 27, 96-106	12.9	12
77	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. *Investigational New Drugs*, **2015**, 33, 700-9	4.3	11
76	Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. *BMC Dermatology*, **2015**, 15, 2	2.1	11
75	Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. *Clinical Epigenetics*, **2015**, 7, 29	7.7	11
74	Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. *Cancer Chemotherapy and Pharmacology*, **2013**, 71, 389-97	3.5	11
73	HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. *Human Pathology*, **2019**, 92, 32-38	3.7	10
72	Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. *Oncotarget*, **2019**, 10, 6526-6535	3.3	10
71	The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagiectoides. *Journal of Clinical and Aesthetic Dermatology*, **2012**, 5, 27-36	1.2	10
70	Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. *Gynecologic Oncology Research and Practice*, **2015**, 2, 10	4.5	9
69	Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. *Clinical Cancer Research*, **2014**, 20, 5956-63	12.9	9
68	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. *Oncotarget*, **2016**, 7, 35132-43	3.3	9
67	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. *Journal of Medical Internet Research*, **2019**, 21, e10348	7.6	9
66	Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors **2020**, 8,		9
65	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. *Scientific Reports*, **2016**, 6, 35448	4.9	9
64	A non-pregnant woman with elevated beta-HCG: A case of para-neoplastic syndrome in ovarian cancer. *Gynecologic Oncology Reports*, **2016**, 17, 49-52	1.3	9
63	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. *Clinical Cancer Research*, **2019**, 25, 7381-7387	12.9	9
62	First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. *Investigational New Drugs*, **2021**, 39, 1047-1056	4.3	9

61	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. *Experimental Hematology and Oncology*, **2020**, 9, 7	7.8	8
60	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. *Journal of Immunotherapy*, **2018**, 41, 284-291	5	8
59	Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. *Journal of Cancer Research and Clinical Oncology*, **2013**, 139, 963-70	4.9	8
58	PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.. *Journal of Clinical Oncology*, **2010**, 28, 2583-2583	2.2	8
57	Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. *Anticancer Research*, **2014**, 34, 2349-55	2.3	8
56	Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. *Investigational New Drugs*, **2015**, 33, 911-20	4.3	7
55	Targeting () Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. *JCO Precision Oncology*, **2019**, 3,	3.6	7
54	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. *Clinical Cancer Research*, **2021**, 27, 3050-3060	12.9	7
53	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. *Cancer*, **2019**, 125, 463-472	6.4	7
52	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. *Oncologist*, **2021**, 26, 558-e1098	5.7	7
51	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. *Investigational New Drugs*, **2015**, 33, 215-24	4.3	6
50	A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib.. *Journal of Clinical Oncology*, **2010**, 28, 2512-2512	2.2	6
49	Associations between the gut microbiome and fatigue in cancer patients. *Scientific Reports*, **2021**, 11, 5847	4.9	6
48	Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case. *American Journal of Dermatopathology*, **2016**, 38, 852-856	0.9	6
47	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. *Scientific Reports*, **2021**, 11, 3667	4.9	6
46	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory **2020**, 8,		5
45	Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 575-81	3.5	5
44	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. *Clinical Cancer Research*, **2020**, 26, 5579-5587	12.9	5

43	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. *Oncologist*, **2021**, 26, 588-596	5.7	5
42	Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. *JCO Clinical Cancer Informatics*, **2018**, 2, 1-14	5.2	5
41	PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. *ESMO Open*, **2021**, 6, 100230	6	5
40	Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. *Clinical Cancer Research*, **2021**, 27, 1681-1694	12.9	5
39	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. *British Journal of Cancer*, **2018**, 118, 1419-1424	8.7	4
38	Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer. *Oncotarget*, **2018**, 9, 33258-33270	3.3	4
37	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. *International Journal of Cancer*, **2021**,	7.5	4
36	Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. *JCO Precision Oncology*, **2019**, 3,	3.6	4
35	A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. *Cancer Chemotherapy and Pharmacology*, **2018**, 82, 877-885	3.5	4
34	First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas **2021**, 9,		4
33	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. *Scientific Reports*, **2020**, 10, 3080	4.9	3
32	Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 194-203	7.3	3
31	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. *Clinical Cancer Research*, **2017**, 23, 4155-4162	12.9	3
30	Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. *Oncology*, **2017**, 92, 14-20	3.6	3
29	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. *Oncotarget*, **2017**, 8, 33796-33806	3.3	3
28	Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel. *Cancer Drug Resistance (Alhambra, Calif)*, **2020**, 3, 636-646	4.5	3
27	Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 19, 700-708	7.3	3
26	Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 1097-102	3.5	3

25	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. *Molecular Cancer Research*, **2021**, 19, 395-402	6.6	3
24	Vandetanib photoinduced cutaneous toxicities. *Cutis*, **2019**, 103, E24-E29	0.4	3
23	Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.. *The Lancet Gastroenterology and Hepatology*, **2022**,	18.8	2
22	A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. *Investigational New Drugs*, **2021**, 39, 1324-1334	4.3	2
21	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. *Npj Precision Oncology*, **2021**, 5, 21	9.8	2
20	Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. *ESMO Open*, **2021**, 6, 100079	6	2
19	Overview of Ocular Side Effects of Selinexor. *Oncologist*, **2021**, 26, 619-623	5.7	2
18	A Phase I Trial of the MET/ Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. *OncoTargets and Therapy*, **2021**, 14, 3037-3049	4.4	2
17	Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. *Advances in Therapy*, **2021**, 38, 4581-4591	4.1	2
16	A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. *Oncotarget*, **2020**, 11, 1235-1243	3.3	1
15	The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors. *Clinical Pharmacokinetics*, **2021**, 60, 921-930	6.2	1
14	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. *Cancer*, **2021**, 127, 391-402	6.4	1
13	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. *Clinical Cancer Research*, **2021**, 27, 1247-1255	12.9	1
12	Report of the First International Symposium on NUT Carcinoma.. *Clinical Cancer Research*, **2022**,	12.9	1
11	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. *Investigational New Drugs*, **2021**, 39, 1357-1365	4.3	0
10	Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. *Cancer Chemotherapy and Pharmacology*, **2021**, 88, 825-836	3.5	0
9	Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. *Investigational New Drugs*, **2021**, 1	4.3	0
8	Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.. *Experimental Hematology and Oncology*, **2021**, 10, 59	7.8	0

7	Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial **2022**, 10, e004822	0
6	Reply to L.D. Locati et al. *Journal of Clinical Oncology*, **2012**, 30, 672-673	2.2
5	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. *Oncotarget*, **2017**, 8, 87163-87173	3.3
4	Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. *Investigational New Drugs*, **2020**, 38, 1166-1174	4.3
3	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. *ESMO Open*, **2020**, 5, e001073	6
2	A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. *Investigational New Drugs*, **2021**, 1	4.3
1	Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. *Investigational New Drugs*, **2021**, 1	4.3